TY - JOUR T1 - Intraluminal Brachytherapy in Unresectable Extrahepatic Biliary Duct Cancer: An Italian Pooled Analysis JF - Anticancer Research JO - Anticancer Res SP - 3417 LP - 3421 DO - 10.21873/anticanres.14326 VL - 40 IS - 6 AU - ROSA AUTORINO AU - SILVIA BISIELLO AU - BRIGIDA PAPPALARDI AU - VANESSA PRIVITERA AU - MILLY BUWENGE AU - FEDERICA PICCOLO AU - CARLOTTA MASCIOCCHI AU - LUCA TAGLIAFERRI AU - GABRIELLA MACCHIA AU - CLELIA DELLE CURTI AU - MARCO LUPPATTELI AU - ANNAMARIA CERROTTA AU - ALESSIO GIUSEPPE MORGANTI AU - VINCENZO VALENTINI AU - GIANCARLO MATTIUCCI Y1 - 2020/06/01 UR - http://ar.iiarjournals.org/content/40/6/3417.abstract N2 - Background/Aim: To evaluate the outcome of patients with unresectable extrahepatic cholangiocarcinoma (CC) treated with external-beam radiotherapy (EBRT) and concurrent chemotherapy (CT) with or without intraluminal brachytherapy (ILBT) boost or with definitive ILBT. Patients and Methods: A pooled analysis of patients with non-metastatic unresectable CC was performed. They were treated in three different institution with EBRT plus CT with or without an ILBT boost. Some patients received only ILBT with curative dose. Results: Seventy-three patients were included in the analysis. Thirty-nine patients (53%) received EBRT treatment with ILBT boost (18 patients with CT during EBRT), while 28 patients (38%) were treated with EBRT (CT in 26 patients) and 6 patients (8.2%) with definitive ILBT (2 patients with CT). CT was administered including either the use of gemcitabine or 5-fluorouracil. With a median follow-up of 16 month (range=1-94 months), median overall survival (OS) was 16 months. Overall median LC was 16 months and patients who underwent ILBT had a better local control (LC) (p=0.018). Conclusion: The role of ILBT in unresectable CC is not yet supported by robust evidence in the literature. However, within this limit, preliminary results seem to suggest an improved local control in patients treated with ILBT, almost comparable to the ones of standard chemo-radiotherapy (CRT). ER -